Press Releases and Publications
Press Releases
Publications
Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the…
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission…
Galveston firm to test potential 'game-changer' in lung disease treatment
GALVESTON An island biopharmaceutical company has received U.S. Food and Drug Administration clearance for its first ever human tests of…
Galveston firm gets $10 million to study radiation antidote
By MYER LEE The Daily News Dec 13, 2020 Darrell Carney’s company, Chrysalis BioTheraputics, received $10.4 million to continue developing…
Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure
December 01, 2020 09:10 AM Eastern Standard Time GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the…
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc.,…
Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development
GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure,…
Drug developed by Galveston scientist to be tested for COVID-19 use
GALVESTON A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems…
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency…
Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508
GALVESTON, Texas, Aug. 21, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan…
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
GALVESTON, Texas, Feb. 7, 2017 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy…
Chrysalis BioTherapeutics receives $3 million grant for nuclear countermeasure development
GALVESTON, TX, May 2, 2016. Chrysalis BioTherapeutics, Inc. today announced receipt of a $3 million grant from the National Institute…
New drug protects against the deadly effects of nuclear radiation 24 hours after exposure
An interdisciplinary research team led by The University of Texas Medical Branch at Galveston reports a new breakthrough in countering…
Chrysalis BioTherapeutics' TP508 Reverses Radiation-Induced GI Damage
GALVESTON, Texas, Aug. 18, 2015 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced publication of data demonstrating that TP508, the company’s lead drug…